Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
Curis (CRIS) Stock Price & Analysis
1,400 Followers
CRIS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.80 - $17.49
Previous Close$6.49
Volume15.15K
Average Volume (3M)28.43K
Market Cap
$38.25M
Enterprise Value-$15.29M
Total Cash (Recent Filing)$56.33M
Total Debt (Recent Filing)$2.79M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Aug 01, 2024EPS Estimate
-$1.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.69
Shares Outstanding5,894,085
10 Day Avg. Volume47,088
30 Day Avg. Volume28,434
Standard Deviation0.70
R-Squared0.07
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)4.39
Price to Sales (P/S)4.68
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.53
Enterprise Value/Gross Profit-1.56
Enterprise Value/Ebitda0.33
Forecast
1Y Price Target
$23.33Price Target Upside259.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Curis News
PremiumCompany Announcements
Curis Inc Showcases Leukemia Study Breakthroughs at Conferences
PremiumPress Releases
Curis Provides First Quarter 2024 Business Update
Bulls Say, Bears Say
Bulls Say
Investor InterestThere is an expectation of increasing investor interest in primary CNS lymphoma with an expected data update from Curis in 15 patients.
Positive DataData from ASH 2023 showed a complete response rate of 60% with Curis' ema combined with ibrutinib.
Treatment AdvantagesCuris has several advantages over axi-cel, including oral administration and a better safety profile.
Bears Say
Clinical DevelopmentPursuing accelerated path in spliceosome mutant patients will require developing a companion diagnostic.
Clinical OutcomesCuris' response rate might pull back in a larger cohort, potentially reducing significant clinical benefit.
Financial PerformanceCapital constraints will become more apparent in the coming quarters.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRIS FAQ
What was Curis Inc’s price range in the past 12 months?
Curis Inc lowest stock price was $3.80 and its highest was $17.49 in the past 12 months.
What is Curis Inc’s market cap?
Currently, no data Available
When is Curis Inc’s upcoming earnings report date?
Curis Inc’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Curis Inc’s earnings last quarter?
Curis Inc released its earnings results on May 07, 2024. The company reported -$2.05 earnings per share for the quarter, missing the consensus estimate of -$2.042 by -$0.008.
Is Curis Inc overvalued?
According to Wall Street analysts Curis Inc’s price is currently Undervalued.
Does Curis Inc pay dividends?
Curis Inc does not currently pay dividends.
What is Curis Inc’s EPS estimate?
Curis Inc’s EPS estimate is -$1.79.
How many shares outstanding does Curis Inc have?
Curis Inc has 5,894,085 shares outstanding.
What happened to Curis Inc’s price movement after its last earnings report?
Curis Inc reported an EPS of -$2.05 in its last earnings report, missing expectations of -$2.042. Following the earnings report the stock price went up 0.186%.
Which hedge fund is a major shareholder of Curis Inc?
Among the largest hedge funds holding Curis Inc’s share is Maverick Capital ltd. It holds Curis Inc’s shares valued at 6M.
---
Curis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.33 (259.48% Upside)
$23.33 (259.48% Upside)
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.61%
12-Months-Change
Fundamentals
Return on Equity
-207.29%
Trailing 12-Months
Asset Growth
-34.40%
Trailing 12-Months
Company Description
Curis Inc
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
---
CRIS Earnings Call
Q1 2024
0:00 / 0:00
---
CRIS Stock 12 Month Forecast
Average Price Target
$23.33
▲(259.48% Upside)
Technical Analysis
Best Analysts Covering CRIS
1 Year
1 Year Success Rate
5/26 ratings generated profit
1 Year Average Return
+10.46%
assigned a buy rating 2 months ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 19.23% of your transactions generating a profit, with an average return of +10.46% per trade.
---